Troutman Pepper Hamilton Sanders LLP

06/22/2021 | Press release | Distributed by Public on 06/22/2021 14:47

Troutman Pepper Advises Inhibikase Therapeutics, Inc. on Follow-On Public Offering

ATLANTA - Troutman Pepper client Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders inside and outside the brain, recently closed its $45 million underwritten public offering of 15 million shares of its common stock at a price to the public of $3.00 per share. Read a company press release about the closing.

Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, which aims to treat Parkinson's disease inside and outside the brain. The company is currently completing its Phase I study of IkT-148009 in older and healthy subjects. Inhibikase plans to use the net proceeds to fund the costs of a Phase 1b extension study for IkT-148009 in Parkinson's patients, the production of IkT-148009 for Phase 1b and Phase 2 clinical studies, and a Phase 2 efficacy trial of IkT-148009 in Parkinson's patients as well as other activities.

ThinkEquity, a division of Fordham Financial Management, Inc., acted as sole book-running manager for the offering. JonesTrading Institutional Services LLC acted as the co-manager for the offering.

A team of Troutman Pepper attorneys, led by Partner Merrill Kraines and Counsel Todd Kornfeld, assisted Inhibikase throughout its public offering. Other Troutman Pepper attorneys included Partner Judy O'Grady, Associate Dean Longfield, and Attorney Noreen Onimus.

Health sciences is a core practice at Troutman Pepper. The firm has more than 150 attorneys who represent clients such as innovative biotech, pharmaceutical and medical device developers and manufacturers; physicians, hospitals and other health care providers; health insurers and other payors; and a wide range of members of the health care supply chain.

About Troutman Pepper
Troutman Pepper is a national law firm with more than 1,200 attorneys strategically located in 23 U.S. cities. The firm's litigation, transactional, and regulatory practices advise a diverse client base, from start-ups to multinational enterprises. The firm provides sophisticated legal solutions to clients' most pressing business challenges, with depth across industry sectors, including health sciences, energy, real estate, insurance, finance, private equity, construction, and technology, among others. Learn more at troutman.com.